JOCELYN NIEMKIEWICZ: Open Payments
NPI 1487038865 · WESTMINSTER, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 32 payments from 11 companies in 2025. Trend: 2023 $469 · 2024 $1,536 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| QOL Medical, LLC | 2 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $28 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Gilead Sciences, Inc. | 1 | $25 |
| PFIZER INC. | 1 | $24 |
| Janssen Biotech, Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
Products named: RINVOQ, ENTYVIO, LINZESS, Sucraid, VOQUEZNA, REZDIFFRA, XELJANZ, TREMFYA.
Industry payments across MD — which companies pay providers there.
